Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review
Lichenoid amyloidosis (LA), a subtype of primary cutaneous amyloidosis (PCA), is featured by intensely pruritic, hyperkeratotic papules which lacks standardized treatment. Dupilumab, a human monoclonal antibody targeting for interleukin (IL)-4/13 receptor α chain, is widely applied in type 2 inflamm...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1485079/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832539879554154496 |
|---|---|
| author | Feiying Guo Feiying Guo Feiying Guo Huajie Zhong Huajie Zhong Yuan Wu Yuan Wu Xue Xu Xue Xu Jiarong Tan Qiang Zhou Shunli Tang Shunli Tang |
| author_facet | Feiying Guo Feiying Guo Feiying Guo Huajie Zhong Huajie Zhong Yuan Wu Yuan Wu Xue Xu Xue Xu Jiarong Tan Qiang Zhou Shunli Tang Shunli Tang |
| author_sort | Feiying Guo |
| collection | DOAJ |
| description | Lichenoid amyloidosis (LA), a subtype of primary cutaneous amyloidosis (PCA), is featured by intensely pruritic, hyperkeratotic papules which lacks standardized treatment. Dupilumab, a human monoclonal antibody targeting for interleukin (IL)-4/13 receptor α chain, is widely applied in type 2 inflammation diseases treatment. This article reported two cases of refractory LA successfully treated with dupilumab and reviewed publications reporting dupilumab treatment for PCA. |
| format | Article |
| id | doaj-art-25ea11f9a4904919869376abe9c52f0e |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-25ea11f9a4904919869376abe9c52f0e2025-02-05T07:32:36ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-02-011210.3389/fmed.2025.14850791485079Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature reviewFeiying Guo0Feiying Guo1Feiying Guo2Huajie Zhong3Huajie Zhong4Yuan Wu5Yuan Wu6Xue Xu7Xue Xu8Jiarong Tan9Qiang Zhou10Shunli Tang11Shunli Tang12Department of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Zhejiang Chinese Medical University, Huzhou, ChinaDepartment of Dermatology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, ChinaDepartment of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Zhejiang Chinese Medical University, Huzhou, ChinaDepartment of Dermatology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, ChinaDepartment of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Zhejiang Chinese Medical University, Huzhou, ChinaDepartment of Dermatology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, ChinaDepartment of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Zhejiang Chinese Medical University, Huzhou, ChinaDepartment of Dermatology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, ChinaDepartment of Otolaryngology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, ChinaDepartment of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Zhejiang Chinese Medical University, Huzhou, ChinaDepartment of Dermatology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, ChinaLichenoid amyloidosis (LA), a subtype of primary cutaneous amyloidosis (PCA), is featured by intensely pruritic, hyperkeratotic papules which lacks standardized treatment. Dupilumab, a human monoclonal antibody targeting for interleukin (IL)-4/13 receptor α chain, is widely applied in type 2 inflammation diseases treatment. This article reported two cases of refractory LA successfully treated with dupilumab and reviewed publications reporting dupilumab treatment for PCA.https://www.frontiersin.org/articles/10.3389/fmed.2025.1485079/fulldupliumabamyloidosisamyloidosis–therapycase reportreview |
| spellingShingle | Feiying Guo Feiying Guo Feiying Guo Huajie Zhong Huajie Zhong Yuan Wu Yuan Wu Xue Xu Xue Xu Jiarong Tan Qiang Zhou Shunli Tang Shunli Tang Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review Frontiers in Medicine dupliumab amyloidosis amyloidosis–therapy case report review |
| title | Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review |
| title_full | Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review |
| title_fullStr | Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review |
| title_full_unstemmed | Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review |
| title_short | Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review |
| title_sort | dupilumab for treatment of primary cutaneous amyloidosis in adults two case reports and literature review |
| topic | dupliumab amyloidosis amyloidosis–therapy case report review |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1485079/full |
| work_keys_str_mv | AT feiyingguo dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT feiyingguo dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT feiyingguo dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT huajiezhong dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT huajiezhong dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT yuanwu dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT yuanwu dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT xuexu dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT xuexu dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT jiarongtan dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT qiangzhou dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT shunlitang dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview AT shunlitang dupilumabfortreatmentofprimarycutaneousamyloidosisinadultstwocasereportsandliteraturereview |